MASP-2 dsRNA Composition for Specific Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with MASP-2 activity, such as autoimmune diseases and thrombosis, lack effective compositions and methods for inhibiting MASP-2 expression.
Innovation Solution
Development of double-stranded RNA (dsRNA) molecules targeting MASP-2 gene expression, comprising specific sense and antisense strands, to inhibit MASP-2 activity through RNA interference.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dsRNA molecules are used to inhibit MASP-2 expression, then therapeutic efficacy for autoimmune diseases and thrombosis is improved, but potential off-target effects and immunogenicity may worsen
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of dsRNA molecules through various nucleotide modifications (2'-O-methyl, 2'-fluoro, phosphorothioate linkages) and adjusting structural parameters (strand length, overhang composition) to reduce immunogenicity and off-target effects while maintaining therapeutic efficacy against MASP-2
Solution Approach 2:
The patent uses modified nucleotides and chemical linkages as intermediaries between the dsRNA molecule and the cellular environment, reducing direct immunogenic interactions while preserving the RNA interference mechanism for MASP-2 inhibition
2Measurement precision
If dsRNA molecules with high specificity to MASP-2 are designed, then inhibition efficacy is improved, but design complexity and development time worsen
Solution Approach 1:
The patent segments the dsRNA molecule into distinct functional regions (sense strand, antisense strand, overhangs) with specific modifications in each region, allowing systematic optimization of specificity while managing design complexity through modular approaches
Solution Approach 2:
The patent applies local quality by introducing specific modifications at particular positions within the dsRNA structure (e.g., 2'-O-methyl at specific nucleotides, phosphorothioate linkages at defined positions) to enhance MASP-2 binding specificity without requiring complete redesign of the entire molecule
3Adaptability or versatility
If dsRNA molecules are administered systemically, then therapeutic coverage is improved, but distribution to target tissues and stability in circulation worsen
Solution Approach 1:
The patent creates composite dsRNA structures combining modified nucleotides, chemical linkages, and structural elements into a single molecule that simultaneously provides circulation stability and tissue distribution capabilities for systemic therapeutic coverage
Solution Approach 2:
The patent ensures continuous protective action through stable dsRNA molecules that maintain their structure and function throughout circulation and tissue distribution, preventing premature degradation while delivering therapeutic effect to target tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA effectively reduces MASP-2 expression, providing therapeutic benefits for conditions like arthritis, IgA nephropathy, and venous thromboembolism by modulating the complement system and preventing uncontrolled inflammatory responses.
Implementation Method 1
double-stranded RNAs (dsRNAs) for inhibiting the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a cell
Data Source
AI summary
Provided are a double-stranded RNA used to inhibit the expression of mannan-binding lectin associated serine protease 2 (MASP2) in cells, a cell containing nucleotides encoding the same, and a method of using the dsRNA or cell to treat diseases or symptoms mediated by or associated with MASP2 expression in subjects.